scholarly journals Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

2020 ◽  
Vol 4 (6) ◽  
pp. s80
Author(s):  
A Blauvelt ◽  
RB Warren ◽  
K Reich ◽  
F Brock ◽  
F Fierens ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Certolizumab Pegol ◽  
Phase 3 ◽  
Two Phase ◽  
Severe Plaque Psoriasis

Abstract not available.

Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

2019 ◽  
Vol 3 ◽  
pp. S37 ◽  
Author(s):  
K Gordon ◽  
R.B. Warren ◽  
A.B. Gottlieb ◽  
A. Blauvelt ◽  
D Thaci ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Certolizumab Pegol ◽  
Phase 3 ◽  
Two Phase

Abstract not available.

Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials

2019 ◽  
Vol 3 ◽  
pp. S38 ◽  
Author(s):  
A.B. Gottlieb ◽  
D Thaci ◽  
C Leonardi ◽  
Y Poulin ◽  
S Kavanagh ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Certolizumab Pegol ◽  
Phase 3 ◽  
Severe Plaque Psoriasis

Abstract not available.

scholarly journals Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

2020 ◽  
Vol 4 (5) ◽  
pp. s44
Author(s):  
K Gordon ◽  
R B Warren ◽  
A B Gottlieb ◽  
A Blauvelt ◽  
D Thaçi ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Certolizumab Pegol ◽  
Phase 3 ◽  
Two Phase

Abstract not available.

Sign in / Sign up

Export Citation Format

Share Document